Analyst Ratings For CRH Medical Corp (TSE:CRH)
Today, TD Securities reiterated its Buy rating on CRH Medical Corp (TSE:CRH) with a price target of C$12.00.
There are 3 hold ratings, 4 buy ratings on the stock.
The current consensus rating on CRH Medical Corp (TSE:CRH) is Buy (Score: 2.57) with a consensus target price of C$10.31 per share, a potential .
Some recent analyst ratings include
- 4/28/2017-TD Securities Reiterated Rating of Buy.
- 2/24/2017-Bloom Burton was Downgraded by analysts at Bloom Burton from a “Buy ” rating to a ” Accumulate” rating.
- 2/24/2017-Beacon Securities Reiterated Rating of Buy.
- 2/15/2017-National Bank Financial Reiterated Rating of Sector Perform.
- 9/13/2016-CIBC Reiterated Rating of Outperform.
About CRH Medical Corp (TSE:CRH)
CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries. The Company specializes in the treatment of hemorrhoids utilizing its treatment protocol and technology. The Company’s product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company’s CRH O’Regan System, platform that provides gastrointestinal is a single use, disposable, hemorrhoid banding technology for treating hemorrhoid grades I-IV. The Company distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a package to physicians. The Company’s subsidiary, Gastroenterology Anesthesia Associates, LLC, provides anesthesiology services for gastroenterology procedures.
Recent Trading Activity for CRH Medical Corp (TSE:CRH)
Shares of CRH Medical Corp closed the previous trading session at 8.03 down -0.34 -4.06% with 927,239 shares trading hands.
